Can MTHFR rs1801133 AG and rs1801131 GT variants reduce activity and increase homocysteine vulnerability when folate or riboflavin is low?

The claim is biologically and clinically plausible at a population level: rs1801133 AG (C677T heterozygosity) can reduce MTHFR function, and nutrient status influences whether this translates into higher homocysteine. The independent contribution of rs1801131 GT (A1298C heterozygosity) is less certain.

Functional and mechanistic evidence

• In human lymphocytes, C677T heterozygotes have about 65–67% of the MTHFR activity seen in CC individuals—approximately a one-third reduction.
• Combined C677T/A1298C heterozygosity has been associated with roughly 40–50% lower in-vitro activity (about 50–60% residual activity) versus the reference genotype.
• MTHFR converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the methyl donor required for remethylation of homocysteine to methionine.
• The C677T variant is more thermolabile and has reduced FAD affinity/stability. Because FAD is riboflavin-derived, inadequate riboflavin could plausibly worsen functional impairment.

Homocysteine and nutrient context

• Folate status is inversely associated with homocysteine across genotypes, and improving folate status can eliminate genotype-group differences in homocysteine.
• The most consistent genotype-associated homocysteine elevations occur in 677TT, not CT/AG carriers. Findings in combined CT/AC carriers are mixed; one study found no significant increase, while others linked reduced activity and unfavorable nutritional status with higher homocysteine.
• Randomized riboflavin evidence is strongest in 677TT individuals: supplementation lowered homocysteine particularly among those with low baseline riboflavin, but not significantly in CT participants.

Clinical implications

• Bottom line: These heterozygous variants may confer nutrient-sensitive susceptibility, not a diagnosis of hyperhomocysteinemia or a fixed clinical risk. Direct measurement of homocysteine, folate, riboflavin, and particularly vitamin B12 is more informative than genotype alone; routine MTHFR testing is not recommended for thrombophilia or recurrent-pregnancy-loss evaluation.